Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer

IMPORTANCE: Poly(adenosine diphosphate–ribose) polymerase inhibitor and anti–programmed death receptor-1 inhibitor monotherapy have shown limited clinical activity in patients with advanced triple-negative breast cancer (TNBC). OBJECTIVE: To evaluate the clinical activity (primary) and safety (secon...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:JAMA Oncol
Glavni autori: Vinayak, Shaveta, Tolaney, Sara M., Schwartzberg, Lee, Mita, Monica, McCann, Georgia, Tan, Antoinette R., Wahner-Hendrickson, Andrea E., Forero, Andres, Anders, Carey, Wulf, Gerburg M., Dillon, Patrick, Lynce, Filipa, Zarwan, Corrine, Erban, John K., Zhou, Yinghui, Buerstatte, Nathan, Graham, Julie R., Arora, Sujata, Dezube, Bruce J., Telli, Melinda L.
Format: Artigo
Jezik:Inglês
Izdano: American Medical Association 2019
Teme:
Original Investigation
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6567845/
https://ncbi.nlm.nih.gov/pubmed/31194225
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2019.1029
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items